Nirogacestat clinical trials
Also written PF-03084014 and Ogsiveo.
How each study uses nirogacestat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nirogacestat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Nov 2023 · OGSIVEO · NDA 217677 (FDA, Drugs@FDA)
- European Union
- 14 Aug 2025 · Ogsiveo · EMEA/H/C/006071 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 9
Pfizer (6) · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (5) · GlaxoSmithKline (3) · AIDS Malignancy Consortium (2) · Children's Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Nam Bui (1)
Often tested with
Tested in the same studies.
Belantamab mafodotin (4) · Dexamethasone (3) · Pomalidomide (2) · Lenalidomide (2) · Famotidine (1) · Rabeprazole (1) · Elranatamab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test nirogacestat.
- Jan 2027Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyPhase 2 · M.D. Anderson Cancer Center
- May 2027A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Phase 2 · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Oct 2027A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentPhase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses nirogacestat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 24
- Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)RecruitingPhase 4SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07176689Written as Nirogacestat
- Nirogacestat in Patients With Kaposi SarcomaRecruitingPhase 2AIDS Malignancy ConsortiumNCT07539454Written as Nirogacestat
- Study of Cryoablation and Nirogacestat for Desmoid TumorRecruitingPhase 2Nam BuiNCT05949099Written as Nirogacestat
- Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT05879146Written as Nirogacestat
- A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple MyelomaRecruitingPhase 1/2Hellenic Society of HematologyNCT05573802Written as Nirogacestat
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by SurgeryActive, not recruitingPhase 2Children's Oncology GroupNCT04195399Written as Nirogacestat Hydrobromide
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Active, not recruitingPhase 2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07170644Written as Nirogacestat oral tablet
- Nirogacestat in Ovarian Granulosa Cell TumorsCompletedPhase 2SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT05348356Written as Nirogacestat
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)CompletedPhase 3SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT03785964Written as Nirogacestat oral tablet
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05556798Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07150104Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07150091Written as Nirogacestat
- Evaluate the Effects of Famotidine or Rabeprazole on the PK of NirogacestatCompletedPhase 1SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNCT07171619Written as Nirogacestat
- Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMActive, not recruitingPhase 1/2GlaxoSmithKlineNCT07084896Written as Nirogacestat
- MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaTerminatedPhase 2PfizerNCT05090566Written as Elranatamab + Nirogacestat
- Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive FibromatosisCompletedPhase 2National Cancer Institute (NCI)NCT01981551Written as PF-03084014
- A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple MyelomaTerminatedPhase 1Precision BioSciences, Inc.NCT04171843Written as Nirogacestat
- A Trial In Patients With Advanced Cancer And LeukemiaCompletedPhase 1PfizerNCT00878189Written as PF-03084014
- A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast CancerTerminatedPhase 1PfizerNCT01876251Written as PF-03084014
- Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer TherapiesTerminatedPhase 2PfizerNCT02109445Written as PF-03084014
See all 24 studies that test nirogacestat →
Given beside what is tested · 4 — nirogacestat is usual care or a partner of the new treatment
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Nirogacestat
- A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple MyelomaActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04722146Written as Nirogacestat
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)CompletedPhase 1Allogene TherapeuticsNCT04093596Written as Nirogacestat
- Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingPhase 1/2GlaxoSmithKlineNCT04126200Written as Nirogacestat
As the comparator · 1 — what is tested is compared with nirogacestat
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Nirogacestat in Patients With Kaposi SarcomaOct 20, 2026NCT07539454
Codes
What other systems call nirogacestat · ClinicalTrials.gg INT005668
- MeSH (NLM) C550722nirogacestatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) QZ62892OFJNIROGACESTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27088329nirogacestatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C82383NirogacestatOne source FDA
- DrugBank DB12005One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C550722 | nirogacestat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QZ62892OFJ | NIROGACESTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088329 | nirogacestat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C82383 | Nirogacestat | One source FDA |
| DrugBank | DB12005 | — | One source Wikidata |
Also registered as nirogacestat hydrobromide (UNII 9T1XY6L45Y).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.